Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2019 Jun;104(6):1268-1276. doi: 10.3324/haematol.2018.205666. Epub 2018 Dec 6.


Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome.

Deconinck S, Tersteeg C, Bailleul E, Delrue L, Vandeputte N, Pareyn I, Itzhar-Baikian N, Deckmyn H, De Meyer SF, Vanderheyden M, Vanhoorelbeke K.

Res Pract Thromb Haemost. 2018 Oct 8;2(4):762-766. doi: 10.1002/rth2.12150. eCollection 2018 Oct.


Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Roose E, Vidarsson G, Kangro K, Verhagen OJHM, Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K.

Thromb Haemost. 2018 Oct;118(10):1729-1742. doi: 10.1055/s-0038-1669459. Epub 2018 Sep 20.


Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13.

Schelpe AS, Orlando C, Ercig B, Geeroms C, Pareyn I, Vandeputte N, Velásquez Pereira LC, Roose E, Fostier K, Nicolaes GAF, Deckmyn H, De Meyer SF, Vanhoorelbeke K, Jochmans K.

Eur J Haematol. 2018 May 15. doi: 10.1111/ejh.13094. [Epub ahead of print]


High and long-term von Willebrand factor expression after Sleeping Beauty transposon-mediated gene therapy in a mouse model of severe von Willebrand disease.

Portier I, Vanhoorelbeke K, Verhenne S, Pareyn I, Vandeputte N, Deckmyn H, Goldenberg DS, Samal HB, Singh M, Ivics Z, Izsvák Z, De Meyer SF.

J Thromb Haemost. 2018 Mar;16(3):592-604. doi: 10.1111/jth.13938. Epub 2018 Jan 31.


Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.

Denorme F, Kraft P, Pareyn I, Drechsler C, Deckmyn H, Vanhoorelbeke K, Kleinschnitz C, De Meyer SF.

PLoS One. 2017 Jun 7;12(6):e0179258. doi: 10.1371/journal.pone.0179258. eCollection 2017.


Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.

Verhenne S, Vandeputte N, Pareyn I, Izsvák Z, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K.

Arterioscler Thromb Vasc Biol. 2017 May;37(5):836-844. doi: 10.1161/ATVBAHA.116.308680. Epub 2017 Mar 2.


N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura.

Tersteeg C, Roodt J, Van Rensburg WJ, Dekimpe C, Vandeputte N, Pareyn I, Vandenbulcke A, Plaimauer B, Lamprecht S, Deckmyn H, Lopez JA, De Meyer SF, Vanhoorelbeke K.

Blood. 2017 Feb 23;129(8):1030-1038. doi: 10.1182/blood-2016-09-738856. Epub 2016 Dec 23.


Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.

Deforche L, Tersteeg C, Roose E, Vandenbulcke A, Vandeputte N, Pareyn I, De Cock E, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K.

PLoS One. 2016 Aug 1;11(8):e0160388. doi: 10.1371/journal.pone.0160388. eCollection 2016.


Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice.

Verhenne S, Denorme F, Libbrecht S, Vandenbulcke A, Pareyn I, Deckmyn H, Lambrecht A, Nieswandt B, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF.

Blood. 2015 Oct 1;126(14):1715-22. doi: 10.1182/blood-2015-03-632901. Epub 2015 Jul 24.


Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.

Feys HB, Roodt J, Vandeputte N, Pareyn I, Mottl H, Hou S, Lamprecht S, Van Rensburg WJ, Deckmyn H, Vanhoorelbeke K.

Blood. 2012 Oct 25;120(17):3611-4. doi: 10.1182/blood-2012-04-421248. Epub 2012 Jul 31.


MRI assessment of blood outgrowth endothelial cell homing using cationic magnetoliposomes.

Soenen SJ, De Meyer SF, Dresselaers T, Vande Velde G, Pareyn IM, Braeckmans K, De Cuyper M, Himmelreich U, Vanhoorelbeke KI.

Biomaterials. 2011 Jun;32(17):4140-50. doi: 10.1016/j.biomaterials.2011.02.037. Epub 2011 Mar 17.


The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet-decorated VWF strings in vivo.

De Maeyer B, De Meyer SF, Feys HB, Pareyn I, Vandeputte N, Deckmyn H, Vanhoorelbeke K.

J Thromb Haemost. 2010 Oct;8(10):2305-12. doi: 10.1111/j.1538-7836.2010.04008.x.


Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).

Feys HB, Roodt J, Vandeputte N, Pareyn I, Lamprecht S, van Rensburg WJ, Anderson PJ, Budde U, Louw VJ, Badenhorst PN, Deckmyn H, Vanhoorelbeke K.

Blood. 2010 Sep 23;116(12):2005-10. doi: 10.1182/blood-2010-04-280479. Epub 2010 Jun 15.


Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura.

Feys HB, Pareyn I, Vancraenenbroeck R, De Maeyer M, Deckmyn H, Van Geet C, Vanhoorelbeke K.

Blood. 2009 Nov 19;114(21):4749-52. doi: 10.1182/blood-2009-07-230615. Epub 2009 Sep 28.


The novel S527F mutation in the integrin beta3 chain induces a high affinity alphaIIbbeta3 receptor by hindering adoption of the bent conformation.

Vanhoorelbeke K, De Meyer SF, Pareyn I, Melchior C, Plançon S, Margue C, Pradier O, Fondu P, Kieffer N, Springer TA, Deckmyn H.

J Biol Chem. 2009 May 29;284(22):14914-20. doi: 10.1074/jbc.M809167200. Epub 2009 Mar 27.


Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.

De Meyer SF, Vandeputte N, Pareyn I, Petrus I, Lenting PJ, Chuah MK, VandenDriessche T, Deckmyn H, Vanhoorelbeke K.

Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1621-6. doi: 10.1161/ATVBAHA.108.168369. Epub 2008 Jun 12.


Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization.

Szántó T, Schlammadinger A, Salles I, Pareyn I, Vauterin S, Hársfalvi J, Vanden Bulcke AM, Deckmyn H, Vanhoorelbeke K.

Thromb Haemost. 2007 Jul;98(1):251-4. No abstract available.


The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha.

Szántó T, Schlammadinger A, Staelens S, De Meyer SF, Freson K, Pareyn I, Vauterin S, Hársfalvi J, Deckmyn H, Vanhoorelbeke K.

Thromb Haemost. 2007 Jul;98(1):178-85.


Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4.

Fontayne A, Vanhoorelbeke K, Pareyn I, Van Rompaey I, Meiring M, Lamprecht S, Roodt J, Desmet J, Deckmyn H.

Thromb Haemost. 2006 Nov;96(5):671-84.


ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.

Feys HB, Liu F, Dong N, Pareyn I, Vauterin S, Vandeputte N, Noppe W, Ruan C, Deckmyn H, Vanhoorelbeke K.

J Thromb Haemost. 2006 May;4(5):955-62.


Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

De Meyer SF, Vanhoorelbeke K, Chuah MK, Pareyn I, Gillijns V, Hebbel RP, Collen D, Deckmyn H, VandenDriessche T.

Blood. 2006 Jun 15;107(12):4728-36. Epub 2006 Feb 14.


False positive results in chimeraplasty for von Willebrand Disease.

De Meyer SF, Pareyn I, Baert J, Deckmyn H, Vanhoorelbeke K.

Thromb Res. 2007;119(1):93-104. Epub 2006 Feb 2.


Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V.

Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, Vanhoorelbeke K, Deckmyn H.

J Biol Chem. 2006 Feb 24;281(8):4699-707. Epub 2005 Dec 22.


Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.

Staelens S, Desmet J, Ngo TH, Vauterin S, Pareyn I, Barbeaux P, Van Rompaey I, Stassen JM, Deckmyn H, Vanhoorelbeke K.

Mol Immunol. 2006 Mar;43(8):1243-57. Epub 2005 Aug 22.


Two functional active conformations of the integrin {alpha}2{beta}1, depending on activation condition and cell type.

Van de Walle GR, Vanhoorelbeke K, Majer Z, Illyés E, Baert J, Pareyn I, Deckmyn H.

J Biol Chem. 2005 Nov 4;280(44):36873-82. Epub 2005 Aug 15.


Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA.

Vanhoorelbeke K, Pareyn I, Schlammadinger A, Vauterin S, Hoylaerts MF, Arnout J, Deckmyn H.

Thromb Haemost. 2005 Jan;93(1):165-71.


Supplemental Content

Loading ...
Support Center